Skip to main content

Table 1 Patient demographics and characteristics at baseline of extension study (SAF)

From: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

 Total (N = 843)
Age, years55.7 (11.9)
Female, n (%)619 (73.4)
Study region, n (%)
 Japan806 (95.6)
 Korea19 (2.3)
 Taiwan18 (2.1)
RA duration at baseline of preceding study, years16.2 (5.6)
Patients in prednisolone dose category, n (%)
 None432 (51.2)
 Average 0 – 5 mg/day341 (40.5)
 Average > 5 mg/day70 (8.3)
Patients receiving concomitant DMARD, n (%)
 None234 (27.8)
 MTX549 (65.1)
 DMARD except for MTX60 (7.1)
Maximum MTX dose for overall period, mg/week9.7 (3.2)
Tender joint count at 68 joints25.1 (7.5)
Swollen joint count at 66 joints24.0 (5.3)
HAQ-DI score30.59 (0.58)
CRP, mg/dL40.87 (1.51)
ESR, mm/h428.4 (22.6)
DAS28-CRP23.03 (1.46)
DAS28-ESR23.63 (1.58)
CDAI score211.59 (11.83)
SDAI score212.47 (12.69)
  1. Data are expressed as mean (SD) unless otherwise stated
  2. 1Duration of RA was calculated as (date of screening visit of preceding study – onset date of RA + 1)/365.25
  3. 2Higher scores indicate greater levels of disease activity
  4. 3Possible HAQ-DI scores range 0 – 3, with higher scores indicating greater disability
  5. 4Higher CRP and ESR values indicate greater inflammation
  6. CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS Disease Activity Score, DMARD disease-modifying antirheumatic drug, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire – Disability Index, MTX methotrexate, RA rheumatoid arthritis, SAF safety analysis set, SD standard deviation, SDAI Simplified Disease Activity Index